LetterBritish journal of haematologyPublished
A phase 1, first-in-human, dose-escalation study of JNJ-74856665 (dihydroorotate dehydrogenase inhibitor) alone or in combination in patients with AML or MDS
22 of 31 authors shown in byline order.
Regional connection
Verified An author affiliation on the Europe PMC record names Johnson & Johnson. Affiliation source
- Institution
- Johnson & Johnson
- County
- Montgomery County
Publication record
- Type
- Letter
- Venue
- British journal of haematology
- Published
- Topic
- Clinical care
- Subject terms
- Acute myeloid leukaemia; Myelodysplastic Syndromes; Phase 1; Dihydroorotate Dehydrogenase; Jnj‐74856665
- PubMed ID
- 40598790
- PubMed Central ID
- PMC12379018
- Open access
- Yes, open
- Added to directory
- Source checked